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httpcense.Abstract Introduction: Early detection of pulmonary hypertension or cor pulmonale could be
beneﬁcial in managing patients with chronic obstructive pulmonary disease (COPD) because the
prognosis of these conditions is poor. Plasma brain natriuretic peptide (BNP) levels are elevated
in patients with PH secondary to chronic lung diseases.
Aim: The aim of the present study was to investigate the use of plasma BNP levels as a prognos-
tic marker in patients with stable COPD.
Methods: Plasma BNP was measured in controls and patients with stable COPD stage II, III and
IV (according to the Global Initiative for Chronic Obstructive Lung Disease classiﬁcation). Echo-
cardiography, arterial blood gas analysis, and spirometry were also performed for COPD patients.
Results: The study included 57 male patients with stable COPD; 19 had stage II COPD, 21 had
stage III COPD, and 17 had stage IV COPD. Twenty age-matched healthy male smokers were
enrolled as a control group. The plasma BNP levels were signiﬁcantly higher in COPD patients
compared to controls. The plasma BNP levels in COPD patients increased with disease severity.
Plasma BNP levels signiﬁcantly correlated with FEV1%, PaCO2, PaO2 and pulmonary artery
systolic pressure.
Conclusions: Plasma BNP levels increased signiﬁcantly with disease severity, progression of
chronic respiratory failure, and secondary pulmonary hypertension in patients with stable COPD.
These results suggest that plasma BNP can be a useful prognostic marker to monitor COPD pro-
gression and identify cases of secondary pulmonary hypertension in patients with stable COPD.
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Brain natriuretic peptide (BNP) was ﬁrst described in 1988
after being isolated from porcine brain [1]. However, this pro-
tein was soon found to originate mainly from the heart and
identiﬁed as a cardiac hormone. The main stimulus responsibleis. Production and hosting by Elsevier B.V.
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BNP levels are elevated several-fold in patients with cor
pulmonale, presumably due to right atrial stretch in response
to increased right ventricular afterload [2]. The biological role
of BNP is probably to attenuate the pulmonary vasopressor
response to alveolar hypoxia [3].
Several large trials have found that the most frequent cause
of death among patients with COPD is cardiac, rather than
respiratory, complications [4,5]. Therefore, secondary pulmon-
ary hypertension and cor pulmonale are important causes of
death and poor prognosis in COPD patients [6,7].
Right heart catheterization has been used for diagnosis and
assessment of the severity of PH and cor pulmonale. However,
recent studies have not demonstrated any sustained beneﬁts of
right heart catheterization for the monitoring of heart failure,
and some have even suggested harm due to adverse events re-
lated to this invasive procedure [8,9].
Plasma BNP is a noninvasive biomarker for the diagnosis
and monitoring of cardiac diseases and heart failure [10,11].
In addition, it is well known that plasma BNP levels are
elevated in patients with cor pulmonale [2]. Although increased
BNP level was reported as a risk factor for death independent
of chronic lung disease [12], few studies have assessed the prog-
nostic value of BNP for determining COPD severity and iden-
tifying the possibility of progression to secondary pulmonary
hypertension. Therefore, the aim of the present study was to
investigate the use of plasma BNP levels as a prognostic mar-
ker in patients with stable COPD.
Materials and methods
Subjects
Patients with stable COPD were enrolled, all were males. The
inclusion criteria were a history of smoking, FEV1/FVC ratio
<70%, and an FEV1 <80% of predicted values. Patients with
conditions altering the levels of plasma BNP were excluded
such as respiratory disorders other than COPD, pulmonary
embolisms, infectious diseases, malignancy, recent surgery,
and cardiac, endocrine, hepatic, or renal dysfunction. Age-
matched healthy smoker males were enrolled as a control
group.
Spirometry
Spirometry was performed for patients and controls using a
computed spirometer (Jaeger, Germany). Spirometry was per-
formed 3 times and the best effort of FEV1 was recorded.
Arterial blood gases analysis
Arterial blood was drawn from COPD patients after a rest per-
iod of 10 min. Arterial partial pressure of oxygen (PaO2) and
carbon dioxide (PaCO2) were measured immediately using an
automatic blood gas analyzer.
Echocardiography
Transthoracic echocardiography was performed for COPD pa-
tients by a cardiologist. The pulmonary artery systolic pressure
(PASP) was analyzed in terms of tricuspid regurgitation peakvelocity (TRPV) and right atrial pressure (RAP) using a col-
or-Doppler technique (PASP = 4 · TRPV+ RAP) [13].
Plasma NT-proBNP
BNP is synthesized as a prehormone (proBNP). Upon release
into circulation it is cleaved into equal amounts of biologically
active C-terminal fragment (BNP), and the biologically inac-
tive N-terminal fragment (NT-proBNP). The half-life of
BNP is 20 min, whereas NT-proBNP has a halﬂife of 120
min. This explains why NT-proBNP plasma values are
approximately six times higher than BNP values, even though
both molecules are released in equimolar proportions. Periph-
eral blood samples were collected in tubes containing ethylene-
diamine tetra-acetate (EDTA). Measurements were performed
using a commercial kit (Roche Diagnostics Corp., Indianapo-
lis, IN, USA) and an electrochemiluminescent method with an
Elecsys 2010 Automated Analyzer (Roche Diagnostics). The
results are presented as pg/ml.
Statistical analysis
All data are expressed as mean and standard error of the mean
(±SEM). One way ANOVA was used to compare variables
among groups. Correlations were determined by Spearman’s
rank correlation test. A p value <0.05 was considered signiﬁ-
cant. Data were analyzed with the Statistical Package for
Social Sciences (SPSS, Chicago, IL, USA).
Results
Clinical characteristics of patients and controls
The study included 57 male patients with stable COPD; 19 had
stage II COPD, 21 had stage III COPD, and 17 had stage IV
COPD. Twenty age-matched healthy male smokers were en-
rolled as a control group. There were no signiﬁcant differences
in age, smoking history (pack-years), or body mass index
among subjects with different stages of COPD and controls
(Table 1).
Plasma BNP levels
The plasma BNP level in COPD patients was signiﬁcantly
higher than that in normal subjects. The levels of plasma
BNP were signiﬁcantly higher in patients with stage IV >
stage III > stage II COPD (Table 2). Plasma BNP levels
signiﬁcantly correlated with FEV1% (r= 0.489; P< 0.01),
PaCO2 (r= 0.501; P< 0.05), PaO2 (r= 0.443; P< 0.05)
and PASP (r= 0.489; P< 0.01).
Discussion
The present study tested the prognostic value of plasma BNP
levels in patients with stable COPD to predict COPD severity,
and complications (pulmonary hypertension). Plasma BNP
levels in patients with stable COPD increased signiﬁcantly with
disease severity and signiﬁcantly correlated with pulmonary
artery systolic pressure.
Plasma BNP levels in patients with stable COPD increased
signiﬁcantly with disease severity. The levels of plasma BNP
Table 1 Characteristics of patients and controls.
Controls (n= 20) Stage II COPD (n= 19) Stage III COPD (n= 21) Stage IV COPD (n= 17) P
Age (years) 67.5 ± 5.1 62.2 ± 3.6 59.8 ± 4.5 69.8 ± 3.2 NS
BMI (kg/m2) 25.2 ± 3.6 26.1 ± 2.2 23.1 ± 3,6 25.4 ± 5.0 NS
Smoking (pack-years) 38.1 ± 7.7 43.0 ± 4.0 51.7 ± 9.3 49.4 ± 8.4 NS
NS, nonsigniﬁcant; BMI, body mass index.
Table 2 Plasma BNP levels, FEV1, arterial blood gases and pulmonary artery systolic pressure in patients and controls.
Controls (n= 20) Stage II COPD (n= 19) Stage III COPD (n= 21) Stage IV COPD (n= 17) P
Plasma BNP (pg/ml) 17.4 ± 4.7 38.0 ± 5.6 59.8 ± 5.1 78.4 ± 6.9 <0.05
FEV1 (% predicted) 89.6 ± 7.5 61.0 ± 6.1 36.9 ± 6.3 36.1 ± 5.7 <0,05
PaO2 (mmHg) – 81.2 ± 8.8 77.9 ± 4.1 61.8 ± 6.3 <0.05
PaCO2 (mm Hg) – 39.2 ± 4.8 46.2 ± 6.1 69.2 ± 7.8 <0.05
PASP (mm Hg) – 37.0 ± 3.8 46.2 ± 4.5 49.8 ± 6.4 <0.05
NS, nonsigniﬁcant; BNP, brain natriuretic peptide; FEV1, forced expiratory volume in 1 s; PaO2, arterial partial pressure of oxygen; PaCO2,
arterial partial pressure of carbon dioxide; PASP, pulmonary artery systolic pressure.
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III > stage II COPD. There have been few studies that exam-
ined plasma BNP levels in patients with stable COPD. Rutten
et al. [14] demonstrated that the overall diagnostic utility of
BNP is lower for detecting heart failure in patients with
chronic dyspnea and COPD than in individuals with acute
dyspnea presenting at the emergency department. Stolz et al.
[15] showed that plasma BNP levels are signiﬁcantly elevated
during acute exacerbation of COPD compared to recovery.
Inoue et al. [16] reported that plasma BNP levels in patients
with stable COPD were signiﬁcantly higher than those of
healthy subjects and patients with severe asthma, and the level
increased signiﬁcantly with disease severity. A high plasma
BNP level was shown to be an independent risk factor for
exacerbation but not mortality [16].
The mechanism underlying high plasma BNP levels in pa-
tients with stable COPD is not clear. Stolz et al. [15] hypothe-
sized that the elevation of BNP levels is at least partly due to
hypoxia-mediated contraction of small pulmonary arterioles,
resulting in increased pulmonary arterial pressure and subse-
quent cardiac stretch. However, this group failed to show a sig-
niﬁcant correlation between plasma BNP levels and PaO2,
PaCO2, or FEV1 [15]. In the present study, we observed signif-
icant differences in plasma BNP levels among patients at dif-
ferent stages of COPD with signiﬁcant correlations between
plasma BNP levels and FEV1%, PaO2, PaCO2 and PASP. This
result can be explained by the fact that decreased FEV1 may
lead to increased air-trapping and hyperinﬂation of the lung.
Such hyperinﬂation is associated with decreased cardiac func-
tion and may result in an increase of plasma BNP. Another
explanation might be related to chronic hypoxia in patients
with COPD resulting in contraction of the small pulmonary
arterioles, increased PASP and subsequently plasma BNP
levels.
In conclusion, we demonstrated that plasma BNP levels sig-
niﬁcantly increased with COPD severity, progression of
chronic respiratory failure, and the presence of secondary
pulmonary hypertension in patients with stable COPD. Our re-
sults suggest that plasma BNP can be a useful prognostic mar-
ker of COPD progression. This factor may also help identifycases of secondary pulmonary hypertension in patients with
stable COPD.References
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